CN102441000B - Anti-cancer anti-disease buccal tablet - Google Patents
Anti-cancer anti-disease buccal tablet Download PDFInfo
- Publication number
- CN102441000B CN102441000B CN 201110420935 CN201110420935A CN102441000B CN 102441000 B CN102441000 B CN 102441000B CN 201110420935 CN201110420935 CN 201110420935 CN 201110420935 A CN201110420935 A CN 201110420935A CN 102441000 B CN102441000 B CN 102441000B
- Authority
- CN
- China
- Prior art keywords
- parts
- polysaccharide
- disease
- buccal tablet
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses an anti-cancer anti-disease buccal tablet which is prepared from the following components in parts by weight: 25-32 parts of yellow fungus polysaccharide, 25-32 parts of Grifola frondosa polysaccharide, 23-29 parts of aweto polysaccharide, 7-12 parts of microcrystalline cellulose, 0.6-2 parts of low-substituted hydroxypropyl cellulose, 2-4 parts of xylitol, 4-7 parts of magnesium stearate and 0.2-0.5 part of essence sodium. The anti-cancer anti-disease buccal tablet is convenient to take and carry and easy to store, has obviously higher bioavailability than common preparations, and provides a convenient administration route for adapting to the present fast-paced living demands and increasingly enhanced living taste.
Description
Technical field
The present invention relates to a kind of buccal tablet, relate in particular to a kind of disease-resistant buccal tablet of cancer that presses down.
Background technology
In recent years, the sickness rate of cancer rises year by year, becomes three large one of diseases that cause death of serious threat human life.At present, for the treatment of cancer, doctor trained in Western medicine is mainly taked operation, radiotherapy, chemotherapy, immunotherapy etc., and four large principles are then followed in Chinese traditional treatment: heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, vanishing sputum and dispelling knot and the body resistance strengthening and constitution consolidating.
The cause of disease of cancer is complicated, of a great variety, and different cancers has different sings and symptomses, tackles cancer and will advocate " three early " early prevention, diagnosis morning, early treatment.Chinese medicine has effect to a plurality of links of tumor; Such as: its righting function can be adjusted immunity, and physical strength reinforcing prevents that tumor from wearing human body down; The function of its Cell differentiation inducing activity, apoptosis and even kill cancer cell can play obvious inhibitory action to the schizogamy of tumor cell; Its elimination " the Carciuogenesis field namely be beneficial to growth of cancer cells, division, breeding arround subenvironment ", improve in the function of environment etc. can prevent the transfer of cancerous cell.Therefore, utilizing Chinese medicine and prophylaxis of tumours is compatriots' Chang Xuan.Although Chinese medicine has the medicine source abundant, untoward reaction is few, advantage that can the flexible prescription of giving treatment in accordance with the patient’s individuality, but it is fried loaded down with trivial details and consuming time and taste is not good enough, the life taste that can not adapt to present allegro life requirement and constantly promote, based on this, the exploitation taking convenience, easily store and portable, and have the buccal tablet dosage form that presses down cancer and disease resisting effect and highlight necessity.
Summary of the invention
For the deficiencies in the prior art, the problem to be solved in the present invention provides a kind of disease-resistant buccal tablet of cancer and preparation method thereof that presses down.
The disease-resistant buccal tablet of cancer that presses down of the present invention is made by the component of following weight portion: 25～32 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 25～32 parts of grifolan, 23～29 parts of Cordyceps polysaccharides, 7～12 parts of microcrystalline Cellulose, 0.6～2 part of low-substituted hydroxypropyl cellulose, 2～4 parts of xylitol, 4～7 parts of magnesium stearate, 0.2～0.5 part in essence sodium.
Further, described buccal tablet is preferably made by the component of following weight portion: 28 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 28 parts of grifolan, 26 parts of Cordyceps polysaccharides, 9 parts of microcrystalline Cellulose, 1 part of low-substituted hydroxypropyl cellulose, 2.7 parts of xylitol, 5 parts of magnesium stearate, 0.3 part in essence sodium.
Wherein: above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan or Cordyceps polysaccharides are produced by upper Haikang boat fungus polysaccharide company limited.
Weight portion of the present invention can be the known mass units of field of medicaments such as μ g, mg, g, kg.
The effective ingredient dosage that presses down the disease-resistant buccal tablet of cancer provided by the invention calculates with the amount that exists in the unit dosage form, and Tremella mesenterica Retz ex Fr. polysaccharide, grifolan and Cordyceps polysaccharides total amount account for 73%～93% in unit dosage form; Preferred embodiment be: (in the 100mg/ sheet) Tremella mesenterica Retz ex Fr. polysaccharide, grifolan and Cordyceps polysaccharides total content account for 82mg in unit dosage form.
The disease-resistant buccal tablet of cancer that presses down of the present invention is to prepare according to the method that those of ordinary skills know, and its basic preparation method is:
In weight portion, unit is kilogram, takes by weighing respectively: 25～32 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 25～32 parts of grifolan, 23～29 parts of Cordyceps polysaccharides, 7～12 parts of microcrystalline Cellulose, 0.6～2 part of low-substituted hydroxypropyl cellulose, 2～4 parts of xylitol, 4～7 parts of magnesium stearate, 0.2～0.5 part in essence sodium.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan, Cordyceps polysaccharides are mixed with microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, xylitol, water is evenly moistening, mixture after moistening is sieved and drying, after sieve, granulate, add magnesium stearate, essence sodium, then with this mixture tabletting, every heavily is 200 ± 10mg.
The present invention is the effective ingredient that presses down the disease-resistant buccal tablet of cancer of the present invention by testing Tremella mesenterica Retz ex Fr. polysaccharide, grifolan, Cordyceps polysaccharides selected, and screened microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, xylitol, magnesium stearate, essence sodium as the adjuvant of this buccal tablet.Wherein the Tremella mesenterica Retz ex Fr. separation of polysaccharides has another name called Tremella mesenterica, Tremella aurantialba Bandoni et Zang, golden Auricularia, yellow ear, brain ear, secretory otitis media etc. from Tremella mesenterica Retz ex Fr.; Its health-care function mainly is: 1. improve the organism metabolism function, the growth of inhibition tumor cell.2. regulate the organism metabolism function, improve the body nutriture, improve the content of body hemoglobin and blood plasma.3. improve body defying age, anti-anoxia ability, blood fat reducing, cholesterol reducing.4. promote liver lipid metabolism, prevent that fat from the liver accumulation, improving liver detoxification function.Grifolan separates from maitake mushroom mycelia, take glucosan as main, take β with β-(1 → 6) branch-(1 → 3) glucosan as basic structure, contains a small amount of xylose and mannose in its polysaccharide component.Result of study shows, grifolan is mainly brought into play its antitumor action by strengthening cellular immune function, on gene level, it has stronger anti-chemical mutagenesis, can be used for behind chronic hepatitis B and the concurrent chemoradiotherapy of malignant tumor weak, leukopenia, the Comprehensive Treatment of Immune Dysfunction, and the prevention of AIDS had certain effect.Cordyceps polysaccharides is the main active substances of rare Chinese medicine Cordyceps, contain 18 seed amino acids, mannitol, the nutrient substance of multivitamin and other multiple needed by human, described polysaccharide is by mannose, cordycepin, adenosine, galactose, arabinose, xylose is smart, glucose, the polysaccharide that fucose forms, pharmacological evaluation shows, its main effect can be protected the lung kidney, mend marrow, only phthisical cough reduces phlegm, multiplex in deficiency of both the lung and kidney disease, energy balance the body immunologic function strengthens resistance against diseases, has anticancer and therapeutical effect, the leucocytes reduction that various diseases is caused has good auxiliary therapeutic action, also has hypoglycemic function.The present invention with the organic combination of said medicine effective ingredient, has made the disease-resistant buccal tablet of cancer that presses down of the present invention with scientific method.Confirm through test: buccal tablet of the present invention can significantly improve immunity of organisms, the resistance against diseases of enhancing body, the invasion and attack of effectively resisting various diseases, and can effectively promote and the enhancing body metabolism, the growth of inhibition tumor cell has positive auxiliaring effect simultaneously in the chronic disease treatment.
The present invention uses the buccal tablet dosage form that the ingredients such as Tremella mesenterica Retz ex Fr. polysaccharide, grifolan, Cordyceps polysaccharides are absorbed by oral cavity or intraesophageal mucosa, the loss that has produced when having avoided effective ingredient to absorb by organs such as human intestines and stomach and livers, improved the absorption rate of pharmaceutical compositions, make bioavailability than the obvious raising of ordinary preparation, realized quick, convenient, efficient administration purpose; It is loaded down with trivial details, consuming time and taste is not good enough that simultaneously buccal tablet of the present invention has overcome Traditional Chinese medicine decocting, and the deficiency that inconvenience is taken, stored and carries is for the life taste that adapts to present allegro life requirement and constantly promote provides again an easily route of administration.
The specific embodiment
The present invention is further elaborated below in conjunction with embodiment, but described protection content is not limited only to this.
Embodiment 1:
In weight portion, unit is kilogram, takes by weighing respectively: 28 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 28 parts of grifolan, 26 parts of Cordyceps polysaccharides, 9 parts of microcrystalline Cellulose, 1 part of low-substituted hydroxypropyl cellulose, 2.7 parts of xylitol, 5 parts of magnesium stearate, 0.3 part in essence sodium.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan, Cordyceps polysaccharides are mixed with microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, xylitol, water is evenly moistening, mixture after moistening is sieved and drying, after sieve, granulate adds magnesium stearate, essence sodium, then with this mixture tabletting, every heavy 200 ± 10mg must press down the disease-resistant buccal tablet of cancer.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan or Cordyceps polysaccharides are produced by upper Haikang boat fungus polysaccharide company limited.
Embodiment 2:
In weight portion, unit is kilogram, takes by weighing respectively: 25 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 25 parts of grifolan, 23 parts of Cordyceps polysaccharides, 7 parts of microcrystalline Cellulose, 0.6 part of low-substituted hydroxypropyl cellulose, 2 parts of xylitol, 4 parts of magnesium stearate, 0.2 part in essence sodium.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan, Cordyceps polysaccharides are mixed with microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, xylitol, water is evenly moistening, mixture after moistening is sieved and drying, after sieve, granulate adds magnesium stearate, essence sodium, then with this mixture tabletting, every heavy 200 ± 10mg must press down the disease-resistant buccal tablet of cancer.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan or Cordyceps polysaccharides are produced by upper Haikang boat fungus polysaccharide company limited.
Embodiment 3:
In weight portion, unit is kilogram, takes by weighing respectively: 32 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 32 parts of grifolan, 29 parts of Cordyceps polysaccharides, 12 parts of microcrystalline Cellulose, 2 parts of low-substituted hydroxypropyl celluloses, 4 parts of xylitol, 7 parts of magnesium stearate, 0.5 part in essence sodium.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan, Cordyceps polysaccharides are mixed with microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, xylitol, water is evenly moistening, mixture after moistening is sieved and drying, after sieve, granulate adds magnesium stearate, essence sodium, then with this mixture tabletting, every heavy 200 ± 10mg must press down the disease-resistant buccal tablet of cancer.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan or Cordyceps polysaccharides are produced by upper Haikang boat fungus polysaccharide company limited.
Embodiment 4:
In weight portion, unit is kilogram, takes by weighing respectively: 30 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 30 parts of grifolan, 28 parts of Cordyceps polysaccharides, 11.5 parts of microcrystalline Cellulose, 1.5 parts of low-substituted hydroxypropyl celluloses, 3.5 parts of xylitol, 5.2 parts of magnesium stearate, 0.3 part in essence sodium.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan, Cordyceps polysaccharides are mixed with microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, xylitol, water is evenly moistening, mixture after moistening is sieved and drying, after sieve, granulate adds magnesium stearate, essence sodium, then with this mixture tabletting, every heavy 200 ± 10mg must press down the disease-resistant buccal tablet of cancer.
Above-mentioned Tremella mesenterica Retz ex Fr. polysaccharide, grifolan or Cordyceps polysaccharides are produced by upper Haikang boat fungus polysaccharide company limited.
Claims (1)
1. one kind is pressed down the disease-resistant buccal tablet of cancer, it is characterized in that described buccal tablet is made by the component of following weight portion: 28 parts of Tremella mesenterica Retz ex Fr. polysaccharide, 28 parts of grifolan, 26 parts of Cordyceps polysaccharides, 9 parts of microcrystalline Cellulose, 1 part of low-substituted hydroxypropyl cellulose, 2.7 parts of xylitol, 5 parts of magnesium stearate, 0.3 part in essence sodium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110420935 CN102441000B (en) | 2011-12-15 | 2011-12-15 | Anti-cancer anti-disease buccal tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110420935 CN102441000B (en) | 2011-12-15 | 2011-12-15 | Anti-cancer anti-disease buccal tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102441000A CN102441000A (en) | 2012-05-09 |
| CN102441000B true CN102441000B (en) | 2013-01-16 |
Family
ID=46004260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110420935 Expired - Fee Related CN102441000B (en) | 2011-12-15 | 2011-12-15 | Anti-cancer anti-disease buccal tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102441000B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103125604A (en) * | 2013-03-27 | 2013-06-05 | 山东大学 | Cancer inhibition health-care milk |
| CN103907911A (en) * | 2013-11-30 | 2014-07-09 | 刘志方 | Compound edible fungus nutritional lozenge |
| CN104397530A (en) * | 2014-12-04 | 2015-03-11 | 阎国红 | Five-mushroom polysaccharide and preparation technology thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019899A (en) * | 2007-03-05 | 2007-08-22 | 澄江县明达园艺有限责任公司 | Buccal tablet of aweto or aweto extract |
| CN101015571B (en) * | 2007-03-13 | 2010-09-08 | 陈林生 | Chinese caterpillar fungus polysaccharide buccal tablets and its preparing process |
| CN101332259B (en) * | 2008-04-29 | 2011-09-21 | 黑龙江新医圣制药有限责任公司 | Cordycepin polysaccharide buccal tablet and preparation method thereof |
-
2011
- 2011-12-15 CN CN 201110420935 patent/CN102441000B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102441000A (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wachtel-Galor et al. | Ganoderma lucidum (Lingzhi or Reishi): a medicinal mushroom | |
| Mayell | Maitake extracts and their therapeutic potential-a review | |
| Chugh et al. | Fungal mushrooms: a natural compound with therapeutic applications | |
| Bandara et al. | Polyporus umbellatus, an edible-medicinal cultivated mushroom with multiple developed health-care products as food, medicine and cosmetics: a review | |
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN102697035A (en) | Cordyceps anti-aging pellet | |
| CN102600212A (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN102755346A (en) | Compound polysaccharide formula of edible fungus as well as preparation method and application thereof | |
| CN101716256B (en) | Preparation used for strengthening immunity | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN102441000B (en) | Anti-cancer anti-disease buccal tablet | |
| CN102784163A (en) | Edible fungi compound polysaccharides health care treatment formula and preparation method thereof | |
| CN103622027B (en) | A kind of hypoglycemia healthcare food composition | |
| JP2002087981A (en) | Improving agent for metabolic disorder against sugar and lipid | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| CN103239470B (en) | Dual-mushroom polysaccharide composition containing coprinus comatus polysaccharide and lentinan as well as preparation method and application thereof | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| TWI601535B (en) | Use of compositions of water/alcohol extracts of antrodia cinnamomea cut-log cultivated fruiting body and solid-state cultivated mycelium as auxiliaries for anti-cancer agents | |
| CN102125571A (en) | Dammarane aglycon compound and application thereof | |
| CN104906140A (en) | Donkey-hide gelatin, a preparation method and associated equipment | |
| CN102379905A (en) | Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance | |
| TW201800099A (en) | The pharmaceutical composition for decreasing the side effects of cancer drug, and manufacturing method and uses thereof | |
| CN101549032B (en) | Drug composition with the effect of anti-lung cancer and application in preparing anti-lung cancer drug | |
| CN1313101C (en) | Chinese medicine for strengthening antitumour thorapeutic effect of glossy ganoderma spore oil | |
| Mushroom et al. | Ganoderma lucidum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130116 Termination date: 20151215 |
|
| EXPY | Termination of patent right or utility model |